Screener
Sutro Biopharma STRO Debt-to-equity
Debt-to-equity at other companies
Other financials
Where this comes from
Calculated from Sutro Biopharma’s reported figures.
Based on the most recent quarter.
The source filing: Sutro Biopharma’s 10-K, filed March 23, 2026. Open the filing →
- Filed
- Mar 23, 2026, 4:44 PM EDT
- Fiscal year
- FY2025
- Accession
- 0001193125-26-119873
FAQ
- What is Sutro Biopharma's debt-to-equity?
- Sutro Biopharma (STRO) reported debt-to-equity of 0.5× in Q4 2024.
- How has Sutro Biopharma's debt-to-equity changed year-over-year?
- Sutro Biopharma's debt-to-equity increased by 130.9% year-over-year, from 0.2× to 0.5×.
- What is the long-term trend for Sutro Biopharma's debt-to-equity?
- Over 4 years (2020 to 2024), Sutro Biopharma's debt-to-equity has grown at a 32.9% compound annual growth rate (CAGR), from 0.2× to 0.5×.
- What does debt-to-equity mean?
- Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.
Ask your AI about Sutro Biopharma's debt-to-equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude